Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on May 26, 2009
JNCI Journal of the National Cancer Institute 2009 101(11):771-773; doi:10.1093/jnci/djp119
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow JNCI Podcast
Right arrow All Versions of this Article:
101/11/771    most recent
djp119v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bosch, F. X.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bosch, F. X.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

EDITORIAL

Broad-Spectrum Human Papillomavirus Vaccines: New Horizons but One Step at a Time

F. Xavier Bosch

Affiliation of author: Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia–Catalan Institute of Oncology, Catalonia, Spain

Correspondence to: F. Xavier Bosch, MD, MPH, Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia–Catalan Institute of Oncology, Avda Gran Via, 199-203, 08907 L'Hospitalet de Llobregat (Barcelona), Catalonia, Spain (e-mail: x.bosch@iconcologia.net; cris@iconcologia.net).

The first 150 words of the full text of this article appear below.

This issue of the Journal presents the results of an experimental project describing the technology and the model system to generate novel human papillomavirus (HPV) vaccines. Rather than using the immune capacity of the L1 capsid epitopes, these prototypes are based on the unique properties of the L2 protein of the capsid to induce broad-spectrum (BS) HPV antigenic recognition and the formation of neutralizing antibodies to a large number of HPV types. The results open the door to a novel family of second-generation HPV vaccines with substantial potential value in the public health horizon.

The developments and the clinical program will still require years of investigation, but the concept addresses in a meaningful way some of the recognized limitations of current vaccines, including the continuous screening requirements and at least partially the difficulties related to the current vaccine cost.

Phase III Results: HPV Type–Specific Protection and Cross-Protection

There are currently two vaccines that have contributed phase III clinical . . . [Full Text of this Article]

Recognized Limitations of Current HPV Vaccines

New Technology in HPV Vaccine Development

Implications of BS HPV Vaccines on Production Cost

Implications of BS HPV Vaccines on Screening Requirements

The Benefits Offered Today by HPV Vaccines and the Responsibility of Deciding the Time to Intervention

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2009 101: 769. [Extract] [Full Text] [PDF]

New Broad-Spectrum Vaccine to Prevent Cervical Cancer Induces Strong Responses in Animals
J Natl Cancer Inst 2009 101: 769. [Extract] [Full Text] [PDF]